Chestnut Venture Partners and Portfolio Companies Honored on 2025 ChinaVenture Top 100 Lists

CV Information Continuously20Year as an independent third-party institution released China Venture Capital Institutions and Private Equity Investment Series Rankings - "CVSource Ranking". Relying on CVSource JiaChuanCVSource, combined with a survey of over a thousand active investment institutions in the private equity field, the CVSource Research Institute reviews data according to selection criteria and selects outstanding institutions. Therefore, the "CVSource Ranking" is known in the industry for its professionalism, authority, and rigor, referred to as the barometer of China's equity investment industry and is recognized by many large institutions.LPAn important basis for investment. On April 24, the 2025 ChinaVenture List was released. Xingze Capital, with its forward-looking industry insights, excellent value discovery capabilities, and full-cycle ecosystem empowerment system, was honored with "Ranked in the TOP 100 of the Best Venture Capital Institutions in China for 2025Awarded "Top 30 Best Biopharmaceutical Investment Institutions in China's Healthcare and Health Services Industry for 2025."Apricot Capital's Partner Companies, Grail Bio and QL Biopharm, Honored「Top 10 Best Biopharmaceutical Investment Cases in China's Healthcare and Health Services Industry for 2025.

Xingze Capital, dedicated to becoming the best entrepreneurial partner, focuses on investing in outstanding early-stage and growth-stage enterprises in the life sciences industry. Its investment projects cover areas such as biopharmaceuticals and medical devices. Leveraging the power of capital, Xingze partners with visionary entrepreneurs to address significant unmet clinical needs globally. Xingze Capital has pioneered an advanced incubation model, empowering multiple projects and achieving remarkable results: the incubated innovative drug companies have achieved an overseas expansion rate of approximately60%, Overseas Transaction CooperationTOP 10Multinational pharmaceutical companies including Johnson & Johnson, AstraZeneca,BioNTech, Roche and Novartis, etc., innovative drug out-licensing20Multiple products, with a total transaction amount reaching450More than X billion US dollars. Only in2024Year1Within the month,4Home Partners completes up to8This ProductLicense-outTransaction, involving three incubated companies (the youngest withMNCSmall molecule biotech company that has reached cooperation) Allorion Bio, (the most external authorizationsADCCompany) Yilian Biotech and (the first small nucleic acid field withMNCArgo Biopharma4The transaction accounts for one-third of the market trading volume, and the total transaction amount exceeds two-thirds of the market's total.2025Year9In the month, Argo Biopharma and Novartis once again joined hands in a strategic partnership, achieving nearly 10 billion in two years for the small nucleic acid king.double kill。

About Gravel Bio

Founded in 2019, QL Biopharm is an innovation-driven biopharmaceutical company in the late clinical stage, committed to pioneering the next generation of immunotherapies for cancer and autoimmune disease patients worldwide. With deep insights into immunotherapy, cutting-edge R&D and technology platforms, and world-class manufacturing capabilities, QL Biopharm has established multiple self-developed technology platforms in China and the United States, along with a diversified pipeline of seven candidate products, to address significant unmet clinical needs. QL Biopharm’s innovative product pipeline includes GT101, a novel autologous tumor-infiltrating lymphocyte (TIL) therapy developed in-house, currently in a pivotal clinical stage for second-line treatment of cervical cancer, as well as six other candidates, including GT719, an innovative off-the-shelf allogeneic chimeric antigen receptor-invariant natural killer T cell (CAR-iNKT) therapy, and GT801, a next-generation in vivo chimeric antigen receptor T-cell (CAR-T) therapy.

About QL Biopharm

QL Biopharm is an innovative biopharmaceutical company focused on the field of metabolic diseases, possessing core competitiveness across the entire chain from drug discovery to industrialization. Relying on its proprietary E. coli technology platform, the company achieves peptide production efficiency far surpassing industry levels, with significant cost advantages and scalability.

QL Biopharm is patient-centered, with a highly differentiated innovative pipeline, leading clinical layout, and solid commercialization prospects. It not only has the world's first once-a-month dosing peptide drug.GLP-1 RAZoveglutide (ZT002) Injection, also has a layout for oral peptidesGLP-1 RA ZT006Tablets, DifferentiationGLP-1/FGF21Dual-target AgonistZT003Injectable and Novel Single-Molecule Long-ActingGLP-1/AmylinRich pipeline coverage including obesity, diabetes,MASHAnd other fields such as neurological diseases. With solid technical accumulation, clear clinical layout, strong industrialization capabilities, and the support of leading market capital, QL Biopharm is steadily emerging as an innovative pharmaceutical company with global competitiveness, committed to continuously improving patients' health and quality of life.